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Azoles inhibit ergosterol biosynthesis, resulting in ergosterol
depletion and accumulation of toxic 14-methylated sterols in
membranes of susceptible yeast. We demonstrated previously
that miconazole induces actin cytoskeleton stabilization in Sac-
charomyces cerevisiae prior to induction of reactive oxygen spe-
cies, pointing to an ancillary mode of action. Using a genome-
wide agar-based screening, we demonstrate in this study that
S. cerevisiae mutants affected in sphingolipid and ergosterol
biosynthesis, namely ipt1, sur1, skn1, and erg3deletionmutants,
aremiconazole-resistant, suggesting an involvement ofmembrane
rafts in its mode of action. This is supported by the antagonizing
effect of membrane raft-disturbing compounds on miconazole
antifungalactivityaswell asonmiconazole-inducedactincytoskel-
etonstabilizationandreactiveoxygenspeciesaccumulation.These
antagonizing effects point to a primary role for membrane rafts in
miconazole antifungal activity.We further show that this primary
role ofmembrane rafts inmiconazole action consists ofmediating
intracellular accumulation ofmiconazole in yeast cells.
The class of azole antimycotics constitutes the largest group
of synthetic antifungal therapeutics currently in clinical use.
The generally accepted mode of antifungal action of azoles is
the inhibition of ergosterol biosynthesis arising from a multi-
mechanistic process initiated by the inhibition of two cyto-
chrome P450 enzymes involved in ergosterol biosynthesis,
namely the P450 enzyme that catalyzes the lanosterol 14-
demethylation step and the P450 enzyme that catalyzes 22
desaturation (1). Azole treatment results in predominance of
14-methylated sterols and inhibition of subsequent reactions
of the ergosterol biosynthesis pathway (1). Apart from inhibi-
tion of ergosterol biosynthesis, miconazole induces accumula-
tion of reactive oxygen species (ROS)3 in susceptible fungi,
leading to fungal cell death (2, 3). Moreover, we have demon-
strated that miconazole induces actin stabilization prior to this
ROS accumulation (4). These data point to an ancillarymode of
action for this azole, as was already suggested in the 1970s (5).
To obtain furthermechanistic insight in themode of antifun-
gal action ofmiconazole, we screened in this study the complete
haploid collection of 4853 Saccharomyces cerevisiae deletion
mutants, individually deleted for nonessential genes, for resist-
ance to miconazole on solid medium. Using this strategy, we
demonstrate that S. cerevisiaemutants affected in sphingolipid
and ergosterol biosynthesis are resistant to miconazole, sug-
gesting a possible involvement of membrane rafts in the mode
of antifungal action of miconazole. These rafts are membrane
patches that are enriched in sphingolipids and ergosterol and
that are thought to compartmentalize the plasma membrane
and to have an important role in cell signaling (6). We investi-
gated the effect of membrane raft-disturbing compounds on (i)
miconazole antifungal activity, (ii) miconazole-induced actin
cytoskeleton stabilization, and (iii) miconazole-induced ROS
accumulation. Furthermore, using HPLC analysis, we investi-
gated the effect of membrane raft disruption on intracellular
accumulation of miconazole in yeast cells.
EXPERIMENTAL PROCEDURES
Materials, Yeast Strains, Plasmids, and Growth Media—Mi-
conazole and methyl--cyclodextrin (MCD) were purchased
from Sigma. Edelfosine was a kind gift from Prof. Christopher
McMaster (Atlantic Research Centre, Dalhousie University,
Halifax, Canada). Acetonitrile was purchased from Fisher
(Leicestershire, United Kingdom). The yeast strains used were
S. cerevisiae strain BY4741 (wild-type (WT)) and the BY4741-
derived deletion mutant library (Invitrogen). These yeast
strains were cultivated in yeast/peptone/dextrose (YPD; 1%
yeast extract, 2% peptone, and 2% glucose). The plasmid encod-
ing green fluorescent protein (GFP)-tagged Pma1p was a kind
gift of Prof. Annick Breton (7). Yeast strains transformed with
this plasmid were cultured in 0.8 g/liter complete amino acid
supplement mixture minus uracil (Bio 101, Inc.), 6.5 g/liter
yeast nitrogen base, and 20 g/liter glucose.
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Screening of a Yeast Deletion Mutant Library for Miconazole
Resistance—The individual yeast deletion mutants were grown
in 96-well microtiter plates containing 100 l of YPD. After
48 h of incubation at 30 °C, the individual deletion mutants
were spotted on YPD-agar plates containing 10 g/ml micon-
azole using a 96-pin replicator for identification ofmiconazole-
resistant yeast deletionmutants. After 48–72 h of incubation at
30 °C, plateswere scored, and resistantmutantswere identified.
Miconazole-resistant mutants were reassessed using the assay
described below.
Quantification of Miconazole Resistance of the Selected Yeast
Mutant—5-l samples of 5-fold serial dilutions of each yeast
cell culture (grown to stationary phase in YPD in microtiter
plates) were spotted on YPD plates containing 0 or 10 g/ml
miconazole. Growth was assessed after 48 h of incubation at
30 °C.
Analysis of Membrane Raft-disturbing Activity of Edelfosine
and Miconazole—Membrane rafts were monitored using
Pma1p as amarker protein (8) byWestern blotting and fluores-
cence microscopy. To this end, membrane rafts were isolated
according to a reported isolation method (8–13). Briefly, a log-
arithmically growing S. cerevisiae culture in YPD (A600  2.0)
was incubated with miconazole (0 or 10 g/ml) or edelfosine
(50 g/ml) for 3 h. Ten A600 units of cells were lysed with glass
beads, and samples were split into two fractions: a homogenate
and a second fraction that was incubated with 1% Triton X-100
for 30 min on ice. The detergent-treated sample was centri-
fuged at 100,000 g for 1 h to yield a detergent-resistant pellet
and a soluble fraction. Proteins were precipitated with trichlo-
roacetic acid and analyzed by gel electrophoresis and immuno-
blotting using an antibody against Pma1p. Additionally, a log-
arithmically growing S. cerevisiae culture transformed with a
plasmid containing GFP-tagged Pma1p was incubated with
either 0 or 10g/ml miconazole or 50g/ml edelfosine for 3 h.
In vivo localization of GFP-tagged Pma1p was performed by
fluorescence microscopy using a Zeiss Axioplan 2 (Carl Zeiss,
Oberkochen, Germany) equipped with an AxioCam charge-
coupled device camera and AxioVision 3.1 software. At least
100 cells weremonitored for each condition. Experiments were
repeated at least three times, and data are means of duplicate
measurements.
Influence ofMembrane Raft-disturbingAgents onMiconazole
Activity—A S. cerevisiae overnight culture in YPD was diluted
to a final concentration of 106 cells/ml in phosphate-buffered
saline (PBS), followed by the addition of various concentrations
of miconazole and edelfosine or MCD. After 4.5 h of incuba-
tion at 30 °C, viability of the yeast culture was assessed by
counting the number of colony-forming units on YPD-agar
plates after 24 h of incubation. Percentage survival was calcu-
lated as the ratio of the number of colony-forming units after
treatment to the number of colony-forming units after the
Me2SO (control) treatment. Experimentswere repeated at least
three times, and data are means of duplicate measurements.
Fluorescence Microscopy for Visualization of the Actin
Cytoskeleton—Rhodamine-phalloidin staining was performed
as described previously for F-actin (14, 15).
Influence of Membrane Raft-disturbing Agents on ROS Accu-
mulation Induced by Miconazole—A logarithmically growing
S. cerevisiae culture in YPD (A600 2.0) was washed and resus-
pended in PBS in the presence of 0 or 10 g/ml miconazole in
combination with various concentrations of edelfosine or
MCD. After 1 h of incubation at 30 °C, 10 M 2,7-dichlo-
rofluorescin diacetate (Molecular Probes, Eugene, OR) was
added (2). The number of fluorescent yeast cells was deter-
mined by fluorescence microscopy (Nikon Optiphot micro-
scope; excitation at 485 nm and emission at 525 nm). Experi-
ments were repeated at least three times, and data are means of
duplicate measurements.
Quantitative Analysis of Intracellular Accumulation of
Miconazole in Yeast Cells—An overnight S. cerevisiaeWT cul-
ture in YPD (108 cells/ml) was washed and resuspended in
PBS (pH 7.4). 100g/mlmiconazole with orwithout 500g/ml
edelfosine or 20mg/mlMCDwas added to 500l of the above
culture. To analyze the intracellular miconazole accumulation
in ipt1 deletionmutant cells, S. cerevisiaeWTand ipt1 deletion
mutant cells were treated with miconazole but without the
addition of edelfosine. After 2.5 h of incubation at 30 °C with
shaking, the supernatant of the yeast cultures was collected.
The cell pellet was washed three times with PBS, followed by
the addition of 300 l of 70% acetonitrile and 30% PBS. The
cells were lysed using a Phastprep reciprocal shaker (Bio 101,
Inc.), and the lysate was clarified by centrifugation (5 min at
3000 rpm). Themiconazole concentration in both the superna-
tant and cell lysates was determined using HPLC based on a
miconazole standard series ranging from 10 to 100 g/ml. The
HPLC system consisted of a LaChrom L-7100 HPLC pump, a
Model L-7420 UV detector set at 260 nm, an L-7200 program-
mable autosampler, and a D-7000 interface (Hitachi, Tokyo,
Japan). 20-l samples were injected twice. UV signals were
monitored, and peaks were integrated using the D-7000 HSM
software (Hitachi). The separation of miconazole was per-
formed on a SunFire C18 3.5-m column (4.6  100 mm;
Waters) equilibrated with 70:30 (v/v) acetonitrile/water. The
column was eluted in an isocratic way at 1.0 ml/min. Experi-
ments were repeated at least three times, and data are means of
duplicate measurements.
Statistical Analysis—Statistical analysis was performed using
the unpaired t test.
RESULTS
Identification of Miconazole-resistant Yeast Deletion Mu-
tants—To obtain more mechanistic insight in the antifungal
mode of action of miconazole, we started our study by screen-
ing a S. cerevisiae deletion mutant library for resistance to
miconazole by replica plating on miconazole-containing YPD-
agar plates. This deletionmutant library consists of single-gene
knock-outs in the S. cerevisiae BY4741 parental strain (WT)
and covers all 4835 open reading frames encoding nonessential
proteins.
First, we determined theminimal inhibitory concentration of
miconazole for the WT strain in YPD-agar plates as 1 g/ml.
Second, screening for miconazole-resistant deletion mutants
was performed on YPD-agar plates containing 10 times the
minimal inhibitory concentration, i.e. 10 g/ml miconazole.
Miconazole Accumulation in Yeast
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Using this genome-wide approach, 12 deletion mutants with at
least 10-fold increased resistance tomiconazole were identified
(Table 1). Two major functional gene groups could be identi-
fied: genes involved in (i) sphingolipid and ergosterol biosyn-
thesis and (ii) mitochondrial function. Additionally, SIP3 and
ADH1 were identified, encoding a transcription factor and an
alcohol dehydrogenase, respectively. Moreover, open reading
frames encoding hypothetical pro-
teins were also identified as micon-
azole sensitivity genes. Resistance of
the individual mutants was con-
firmed and quantified using yeast
dilutions on agar with and without
miconazole (Fig. 1).
Becausemiconazole induces ROS
accumulation in susceptible fungi
(2–4), it is not surprising that we
identified yeast deletion mutants
affected in mitochondrial function
to be resistant to miconazole.
Hence, in this study, we focused on
the class of miconazole sensitivity
genes involved in sphingolipid and
ergosterol biosynthesis, i.e. IPT1,
SKN1, SUR1, and ERG3. Only yeast
mutants displaying at least 10-fold
increased miconazole resistance in
agar were selected. Other mutants
in genes involved in ergosterol or
sphingolipid biosynthesis seem to
be characterized by less pro-
nounced miconazole resistance.
Role ofMembrane Rafts inMicon-
azole Antifungal Activity—In fungal
membranes, sphingolipids and
ergosterol are preferentially located
in specific domains termed mem-
brane rafts. Membrane rafts are
thought to compartmentalize the
plasma membrane and to have an important role in cell signal-
ing (6). Becausewe foundmutants affected in both sphingolipid
and ergosterol biosynthesis to be miconazole-resistant, we
hypothesized that membrane rafts play an important role in
miconazole antifungal action. To test this hypothesis, we
treated S. cerevisiae WT cells with membrane raft-disturbing
agents, namely edelfosine and MCD to phenocopy mutants
FIGURE 1. S. cerevisiae deletion mutants that are miconazole-resistant. 5-l samples of 5-fold serial dilu-
tions of each yeast culture (rows)were spottedonYPDplates containing0g/mlmiconazole (left panel) and10
g/ml miconazole (right panel). Plates were incubated at 30 °C for 48 h.
TABLE 1
Genes that result in miconazole resistance upon deletion in S. cerevisiae
Gene ORFa Description of gene product
Ergosterol and sphingolipid biosynthesis
ERG3 YLR056W C-5 sterol desaturase, catalyzes the introduction of a C(5)-C(6) double bond into
episterol, a precursor in ergosterol biosynthesis
SKN1 YGR143W Protein involved in sphingolipid biosynthesis
IPT1 YDR072C Inositol phosphotransferase 1, involved in synthesis of mannosyldiinositol
phosphorylceramide
SUR1 YPL057C Probable catalytic subunit of mannosylinositol phosphorylceramide synthase
Mitochondrial function
PTH1 YHR189W One of two mitochondrially localized peptidyl-tRNA hydrolases
MRPL23 YOR150W Mitochondrial ribosomal protein of the large subunit
YDR114C Hypothetical protein; deletion mutant is respiratory-deficient
Gene expression
SIP3 YNL257C Protein that activates transcription through interaction with DNA-bound Snf1p,
potential Cdc28p substrate
Varia
ADH1 YOL086C Alcohol dehydrogenase
YOR292C Hypothetical protein
YDR068W Hypothetical protein
YPL056C Hypothetical protein
aOpen reading frame.
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affected in proper membrane raft composition and analyzed
whether these agents can modulate miconazole antifungal
activity. Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-
phosphocholine) is an anticancer lysophospholipid that inter-
feres with sphingolipid metabolism and alters the organization
and composition of lipid rafts (16).MCD is a sterol-sequester-
ing agent that is commonly used to disturbmembrane rafts (17,
18). Administration of 10 g/ml miconazole to a 1:100 diluted
overnight culture of S. cerevisiae WT cells resulted in 0.1%
survival, whereas simultaneous addition of 50 or 100 g/ml
edelfosine and miconazole resulted in increased survival of the
yeast culture (72.6  9.5 or 99.0  4.5% survival, respectively;
p 0.01). Similar results were obtained with MCD. Simulta-
neous addition of 1.2 or 2.5 mg/ml MCD and miconazole
resulted in increased survival of the yeast culture (10.9 2.5 or
99.0 4.5% survival, respectively; p 0.025). Apparently, dis-
ruption of membrane rafts leads to a decrease in miconazole
antifungal activity and hence antagonizes miconazole action.
To analyze whether miconazole itself disrupts membrane rafts,
we used Pma1p as a marker to monitor lipid rafts (8). Fraction-
ation revealed normal enrichment of Pma1p in the raft frac-
tions of control and miconazole-treated WT cells (Fig. 2A),
indicating thatmiconazole does not disruptmembrane rafts. In
cells treated with edelfosine, Pma1p was present in the soluble
fraction (Fig. 2A), indicating that under these conditions edel-
fosine indeed disrupts the association of Pma1p with mem-
brane rafts. This was corroborated by fluorescence microscopy
analysis, which revealed normal localization of Pma1p in the
plasma membrane upon miconazole treatment and mislocal-
ization of Pma1p in punctuate structures upon edelfosine treat-
ment (Fig. 2B and Table 2). Non-raft-associated Pma1p is
known to be endocytosed from the plasma membrane and
degraded by targeting to the vacuole (8–11). These results
show that miconazole itself does not disrupt membrane rafts.
Role of Membrane Rafts in Miconazole-induced Pheno-
types—Because miconazole induces stabilization of the actin
cytoskeleton prior to induction of ROS in yeast cells (4), we
analyzed whether disruption of membrane rafts affects these
phenotypes. To this end, we treated a logarithmically growing
S. cerevisiae culture with 10 g/ml miconazole in the presence
of membrane raft-disturbing agents and analyzed induction of
actin cytoskeleton stabilization and ROS accumulation. First,
miconazole (0 or 10 g/ml) with or without edelfosine (100
g/ml) or MCD (2.5 mg/ml) was added to S. cerevisiae cells.
Samples were taken after 4 h of incubation at 30 °C to deter-
mine the effect of membrane raft disruption on actin cytoskel-
eton stabilization induced by miconazole. A normal organiza-
tion of cortical actin patches and polarized actin cables was
clearly observed in untreated cells or in cells treated with edel-
fosine or MCD (Fig. 3). The addition of 10 g/ml miconazole
resulted in aggregation of F-actin as described previously (4).
Combined treatment of the yeast cells with miconazole and
edelfosine or MCD resulted in alleviation of the miconazole-
induced F-actin aggregation. These results demonstrate that
disruption of membrane rafts antagonizes the aggregation of
F-actin induced by miconazole.
FIGURE 3. Lipid raft disruption affects miconazole-induced stabilization
of the actin cytoskeleton.A logarithmically growing S. cerevisiaeWT culture
in YPDwas diluted in PBS and treated with 0 or 10g/ml miconazole with or
without 100 g/ml edelfosine or 2.5 mg/ml MCD. After 4 h of incubation at
30 °C, cells were fixed and stained with rhodamine-phalloidin to determine
organization of F-actin structures. Scale bars 5 m.
TABLE 2
Percentage of cells with Pma1p-GFP localized intracellularly or at the
cell perimeter
Treatment
Cellsa
Pma1p-GFP
internalized
Pma1p-GFP not
internalized
%
Me2SO 2.7 0.5 97.3 0.5
Miconazole 2.4 0.3 97.6 0.3
Edelfosine 70.5 3.5 29.5 3.5
a Percentage of cells with the specified phenotype was determined as the ratio of
cells with the specified phenotype (as visualized by fluorescence microscopy) to
the total number of cells (n 100).FIGURE 2. Effect of edelfosine and miconazole on membrane rafts in
S. cerevisiaeWT cells. A logarithmically growing S. cerevisiae WT culture in
YPD was incubated with either 0 or 10 g/ml miconazole or 50 g/ml edel-
fosine for 3hat 30 °C.A, raft associationof Pma1pwasexaminedbydetergent
extraction in the following fractions: homogenate (H), detergent-resistant
pellet (P), and soluble fraction (S). Proteins were precipitated by trichloroace-
tic acid and analyzed by gel electrophoresis and immunoblotting using an
antibody against Pma1p. B, Pma1p-GFP localization was analyzed by fluores-
cence microscopy. Scale bars 5 m.
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Second, treatment of S. cerevisiae cells with 10g/mlmicon-
azole resulted in 26.7 2.4% ROS-positive cells, whereas com-
bined treatment of the yeast cells with miconazole and edelfos-
ine or MCD resulted in a decrease in ROS-positive cells
(namely 8.1  1.1 or 7.2  1.0% ROS-positive cells upon co-
incubation with 50 or 100 g/ml edelfosine, respectively (p 
0.01); and 8.3  1.8 or 9.0  2.4% ROS-positive cells upon
co-incubation with 1.2 or 2.5 mg/ml MCD, respectively (p
0.025)). The percentage of ROS-positive cells of a yeast culture
upon control treatment (i.e. Me2SO control) was 4.7  1.9%.
These data indicate that the addition of either edelfosine or
MCD antagonizes miconazole-induced ROS accumulation in
S. cerevisiae. Hence, we demonstrated that disruption of mem-
brane rafts via edelfosine or MCD antagonizes both the actin
cytoskeleton stabilization and endogenous ROS accumulation
induced by miconazole.
Effect of Membrane Raft Disruption on Intracellular Accu-
mulation of Miconazole in Yeast Cells—Based on all data, it is
clear thatmembrane rafts play an important primary role in the
mode of antifungal action ofmiconazole. Therefore, we focused
on a putative involvement of membrane rafts in intracellular
accumulation ofmiconazole and analyzedmiconazole accumu-
lation in yeast cells in the presence and absence of edelfosine or
MCD. To this end, we treated a non-diluted overnight culture
of S. cerevisiae WT cells in YPD with 100 g/ml miconazole
with or without 500g/ml edelfosine. After 2.5 h of incubation,
we determined the concentration ofmiconazole in the cells and
in the corresponding supernatant via HPLC analysis. Treat-
ment of the cells withmiconazole resulted in intracellular accu-
mulation of 97.4  1.5% miconazole, whereas 2.6  1.5%
miconazole was left in the corresponding supernatant of the
treated cells. Co-incubation of the culture withmiconazole and
edelfosine resulted in 2-fold reduced intracellular accumula-
tion of miconazole, namely 55.1  5.7% intracellular micon-
azole and 44.9 2.3%miconazole remaining in the supernatant
(p 0.01). The corresponding survival percentages using these
specific experimental conditions (increased inoculum and
increased concentrations of miconazole and edelfosine) were
1.3% for miconazole-treated culture versus 40.3% for micon-
azole- and edelfosine-treated culture, pointing to a correlation
between intracellular miconazole accumulation and its fungi-
cidal activity. Similar results were obtained with MCD. Com-
bined treatment of the yeast cells with 100 g/ml miconazole
and 20 mg/ml MCD resulted in 2-fold reduced intracellular
accumulation of miconazole, namely 54.3 0.7% intracellular
miconazole and 45.7  0.7% miconazole remaining in the
supernatant (p  0.001). In summary, these results document
the essential role for membrane rafts in the intracellular accu-
mulation and killing potential of miconazole.
Because membrane rafts are patches that are enriched in
sphingolipids and ergosterol, we further analyzed whether the
reduced miconazole susceptibility of the miconazole-resistant
deletion mutants can be explained by reduced intracellular
miconazole accumulation. To this end, we treated non-diluted
overnight cultures of S. cerevisiaeWTand ipt1 deletionmutant
cells with 100g/mlmiconazole. Treatment of the S. cerevisiae
WT cells with miconazole resulted in 96.0 1.2% intracellular
miconazole accumulation. Treatment of the ipt1 deletion
mutant cells with miconazole resulted in only 67.0  1.8%
intracellularmiconazole accumulation (p 0.01). This reduced
accumulation in the ipt1 deletion mutant can explain its
reduced sensitivity to miconazole treatment.
DISCUSSION
To obtain more mechanistic insight in the mode of antifun-
gal action of miconazole, we screened the complete set of hap-
loid deletionmutants of S. cerevisiae for increased resistance to
miconazole in agar. As such, we identified 12 miconazole sen-
sitivity genes, which, upon deletion, result in at least 10-fold
increased resistance tomiconazole. In this study, we focused on
the functional group ofmiconazole sensitivity genes implicated
in sphingolipid and ergosterol biosynthesis, represented by
IPT1, SKN1, SUR1, and ERG3. The role of ERG3 in azole resist-
ancewas already demonstrated because treatment of yeast with
azoles results in the accumulation of 14-methylated sterols
and 14-methylergosta-8,24(28)-dein-3,6-diol (19, 20). Forma-
tion of the latter sterol metabolite is thought to be catalyzed by
5,6-desaturase (encoded by ERG3). Hence, inactivation of
ERG3 can suppress toxicity and therefore cause azole resistance
(19, 20). Additionally, we found various mutants affected in
sphingolipid biosynthesis to be miconazole-resistant, suggest-
ing a possible role for membrane rafts in miconazole antifungal
action. Sphingolipids and ergosterol are enriched inmembrane
domains termed membrane rafts. Membrane rafts are thought
to compartmentalize the plasma membrane and to have an
important role in cell signaling (6).We have demonstrated that
disruption of these rafts by treatment with edelfosine orMCD
interferes with miconazole antifungal action as well as with
miconazole-induced stabilization of the actin cytoskeleton and
ROS accumulation. These data point to an important primary
role for membrane rafts in miconazole antifungal action. Using
HPLC analysis, we further demonstrated that co-incubation of
miconazole and either lipid raft-disturbing agent results in
reduced intracellular accumulation ofmiconazole in yeast cells.
In conclusion, administration of agents that disturb lipid
rafts in the plasma membrane, by affecting either sphingolipid
biosynthesis or ergosterol sequestration (i.e. edelfosine or
MCD, respectively), abolishes the antifungal action and accu-
mulation of miconazole. Whether the reduced intracellular
accumulation of miconazole upon treatment of yeast cells with
membrane-disturbing compounds is caused by a reduced
uptake in yeast cells or by increased efflux remains to be deter-
mined. Moreover, the miconazole-resistant ipt1 deletion
mutant showed reduced intracellular miconazole accumula-
tion, correlating intracellular accumulation of miconazole with
yeast cell death.
A general role for plasmamembrane (phospho)lipid and ste-
rol composition in azole accumulation is postulated (21, 22). In
a study tracking the development of low-level fluconazole
resistance in Candida albicans, a gradual increase in mem-
brane fluidity of fluconazole-adapted strains was demon-
strated, whereas the phospholipid composition of the adapted
strains was not significantly altered (21). However, ergosterol
content was reduced, whereas sphingolipid content was higher
in resistant than in susceptible isolates. Hence, that study dem-
onstrates that altering the ratio of ergosterol to sphingolipid
Miconazole Accumulation in Yeast
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content influences susceptibility to fluconazole. Moreover,
Lo¨ffler et al. (22) compared the plasmamembrane composition
of five fluconazole-resistant C. albicans isolates with that of
three fluconazole-sensitive ones. They demonstrated that one
resistant C. albicans isolate had a decreased amount of ergos-
terol and a lower phosphatidylcholine/phosphatidylethanol-
amine ratio in the plasma membrane. They postulated that
these changes in plasma membrane lipid and sterol composi-
tion could be responsible for an altered uptake of fluconazole
and hence for reduced intracellular fluconazole accumulation.
Whether membrane rafts are involved in intracellular accumu-
lation of azoles in general remains to be determined.
To our knowledge, this is the first report describing a role for
a specific membrane compartment in intracellular accumula-
tion of miconazole. Because membrane rafts have been sug-
gested to be involved in endocytosis (23), it remains to be deter-
mined whether miconazole is taken up in S. cerevisiae cells by
endocytosis. If so, our observed reduction of miconazole accu-
mulation in yeast with disturbed membrane rafts could be
explained by a reduced uptake of the drug.
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